Top
Crohn’s Disease - Healing Genes
723
post-template-default,single,single-post,postid-723,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Crohn’s Disease

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Treatment of Perianal Disease Using Adipose-derived Stem Cells


Phase Not Applicable

DESCRIPTION:

Doctors at the University of California San Diego are recruiting patients with perianal fistula, including those caused by Crohn’s Disease, to receive an experimental treatment that transfers adipose (fat tissue)-derived stem cells to the fistula lesion.

This investigatory treatment aims to assure the effectiveness of the treatment in comparison with standard surgical care.


PATIENT MUST:

  • Be 18 years of age and older
  • Diagnosis of perianal disease with tissue defect or chronic wound
  • Not be pregnant

THE STUDY INVOLVES:

  1. Prescreening at the study site to confirm eligibility of the patient to participate.
  2. Stem cells will be drawn from the patient’s adipose, or fat, tissue, by liposuction method.
  3. During the same surgery, a colorectal surgeon will perform an exam and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed.
  4. Then the surgeon will inject the adipose stem cells, after they are processed by the Acelity machine, into the perianal fistula.

LOCATIONS AND CONTACTS:

Trials will take place at the University of California San Diego. Map.

Contact: Samuel Eisenstein, MD  |  203-560-2213  |  [email protected]

Contact: Sarah Stringfield, MD  |  920-319-1697  |  [email protected]

 

SPONSOR INFORMATION:

University of California, San Diego

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03913572

 

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader